FDA Approval Alert: The Need-to-Know | Inotuzumab Ozogamicin in Pediatric CD22+ ALL

In March 2024, the FDA approved inotuzumab ozogamicin as a treatment for pediatric patients who are 1 year or older diagnosed with relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.

Findings from an open-label trial support the FDA approval of inotuzumab ozogamicin as a treatment for pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
FDA Approves Inotuzumab Ozogamicin in Pediatric CD22+ ALL
Article
Mar 6, 2024 9:32 PM
Findings from an open-label trial support the FDA approval of inotuzumab ozogamicin as a treatment for pediatric patients with relapsed/refractory acute lymphoblastic leukemia.